Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW, van Weelden WJ, Visser NCM, Bulten J, van der Putten LJM, van de Vijver K, Santacana M, Colas E, Gil-Moreno A, Moiola CP, Mancebo G, Krakstad C, Trovik J, Haldorsen IS, Huvila J, Koskas M, Weinberger V, Bednarikova M, Hausnerova J, van der Wurff AA, Matias-Guiu X, Amant F; ENITEC Consortium; Snijders MPLM, Küsters-Vandevelde HVN, Reijnen C, Pijnenborg JMA.
Vrede SW, et al. Among authors: bednarikova m.
Gynecol Oncol. 2021 Jun;161(3):787-794. doi: 10.1016/j.ygyno.2021.03.031. Epub 2021 Apr 12.
Gynecol Oncol. 2021.
PMID: 33858677
Free article.